



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Yutaro KANEKO, et al.

SERIAL NO: 09/087,513

GAU: 1632

FILED: May 29, 1998

EXAMINER: M. WILSON

FOR: ALTERED ENVELOPE GLYCOPROTEIN FOR HIV VACCINE AND TREATMENT OF PATIENTS WITH HIV INFECTION

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

### REFERENCES

- The applicant(s) wish to make of record the references listed on the attached European Office Action and Form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

### RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

### CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

### DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

  
Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

James J. Kelly  
Registration No. 41,504



Form PTO 1449 (Modified)  LIST OF REFERENCES CITED BY APPLICANT		ATTY DOCKET NO. 0010-0929-0X		SERIAL NO. 09/087,513		
		APPLICANT Yutaro KANEKO, et al.				
		FILING DATE May 29, 1998		GROUP 1632		
		U.S. PATENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS SUB CLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES      NO	
	AO	WO 97/24447	07/10/97	WIPO		
	AP	WO 94/22477	10/13/94	WIPO		
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)						
	AW	Journal of Virology, vol. 66, No. 12, Dec. 1, 1992, pp. 6997-7004, Richard Wyatt, et al., "RELATIONSHIP OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp120 THIRD VARIABLE LOOP TO A COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579276 ISSN: 0022-538X.				
	AX	C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATION OF HIV-1 gp160 PARTIALLY OR COMPLETELY DELETED IN THE V3 LOOP", XP002155492 ISSN: 0764-4469.				
	AY	Journal of Virology, vol. 67, No. 11, Nov. 1993, pp. 6897-6902, Nicole K. T. Back, et al., "MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY gp120 ANTIBODIES"				
	AZ	Sarah L. Rowland-Jones, et al., Immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIV-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED PERSISTENTLY SERONEGATIVE DONORS"			<input checked="" type="checkbox"/> Additional References sheet(s) attached	
Examiner				Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

O I P F  
NOV 25 2003  
U.S. PATENT AND TRADEMARK OFFICE

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. 0010-0929-0X	SERIAL NO. 09/087,513
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Yutaro KANEKO, et al.		
		FILING DATE May 29, 1998	GROUP 1632	
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>				
	AAA	Irena Kiszka, et al., Journal of Virology, May 2002, pp. 4222-4232, "EFFECT OF THE V3 LOOP DELETION OF ENVELOPE GLYCOPROTEIN ON CELLULAR RESPONSES AND PROTECTION AGAINST CHALLENGE WITH RECOMBINANT VACCINIA VIRUS EXPRESSING gp160 OF PRIMARY HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ISOLATES"		
	AAB	Dariusz Kmiecik, et al., The Journal of Immunology, 1998, vol. 160, pp. 5676-5683, "THE EFFECT OF DELETION OF THE V3 LOOP OF gp120 ON CYTOTOXIC T CELL RESPONSES AND HIV gp120-MEDIATED PATHOGENESIS <sup>1</sup> "		
	AAC			
	AAD			
	AAE			
	AAF			
	AAG			
	AAH			
	AAI			
	AAJ			
	AAK			
	AAL			
	AAM			
	AAN			
	AAO			
	AAP			
	AAQ			
Examiner			Date Considered	
<small>*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>				